Debate: Steroids Should be Used Early in the Treatment of Refractory DME | ASCRS
Menu
Home Clinical Education Debate: Steroids Should be Used Early in the Treatment of Refractory DME
Presentation
Debate: Steroids Should be Used Early in the Treatment of Refractory DME
April 2022
Meeting: 2022 ASCRS Annual Meeting
Session: SYM-2 - Retina 2022: Curated for the Anterior Segment Surgeon
Presenter: Rajesh C Rao, MD
This content is only available to 2022 ASCRS Annual Meeting physician registrants

To log in, click the teal "Login" button in the upper right-hand corner of this page. If you are logged in but still do not have access, please check your 2022 Annual Meeting registration.

Filed Under
Retina diabetic macular edema DME medication steroids
View More Presentations from SYM-2

This presentation is from the session "SYM-2 Retina 2022: Curated for the Anterior Segment Surgeon" from the 2022 ASCRS Annual Meeting held on April 22-26, 2022 in Washington, DC.

View More From This Session
Browse All 2022 ASCRS On Demand Sessions

Related Content

Presentation
Cataract Surgery in Patients with Retinal Disease
Lisa C. Olmos de Koo, MD, MBA, ABO 14:33 minutes
April 2022
Presentation
Debate: Steroids Should Not be Used Early in the Treatment of Refractory DME
William F. Mieler, MD, FACS, ABO 08:14 minutes
April 2022
Presentation
Macular Edema After Phaco Report of a Challenging Case
Ricardo Nose, MD; Ana Carolina Canedo D. Lima, MD 07:04 minutes
May 2019
Poster
A New Class of IOL, Designed Specifically for Patients with Centre-Involving Macular Disorders. a Case Report
Andreas Borkenstein, MD; Eva-Maria Borkenstein
May 2019
American
About ASCRS
Clinical Education
Meetings
Tools
ASCRS foundation
Donate
Contact Us

© 2023 ASCRS. All Rights Reserved.

Advertise Legal Notice

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.